Welcome to our dedicated page for Enovis news (Ticker: ENOV), a resource for investors and traders seeking the latest updates and insights on Enovis stock.
Enovis Corporation reports recurring developments as a medical technology company focused on reconstructive surgery, rehabilitation, pain management, physical therapy and musculoskeletal care. Company news centers on financial results, guidance, organic sales trends and segment performance in Reconstructive and Prevention & Recovery, including updates tied to new product introductions and end-market conditions.
Enovis announcements also include conference participation and investor presentation activity, with business commentary on clinically differentiated solutions intended to enhance patient outcomes, restore motion and support surgeons, clinicians and other healthcare professionals.
Enovis (NYSE: ENOV) reported first-quarter 2026 net sales of $589 million, up 5% reported and 3% organic year-over-year. Recon sales grew 11% reported (6% organic); P&R was flat reported (1% organic). Enovis reported a first-quarter net loss of $8 million and adjusted EBITDA of $104 million (17.6% margin). The company reaffirmed 2026 guidance: revenue of $2.31–2.37 billion, adjusted EBITDA of $425–435 million, adjusted EPS of $3.52–3.73, and free cash flow conversion of 25% or higher.
Knoa Pharma (V) began operations on May 1, 2026 as a public health–focused pharmaceutical company wholly owned by the not‑for‑profit Knoa Foundation (a 501(c)(4)).
The company will manufacture existing medicines, including opioid analgesics, under a strict operating injunction with independent monitoring, will not promote opioid products, and will use value generated to fund opioid abatement and no‑profit access to overdose reversal and OUD treatments.
Enovis (NYSE: ENOV) will host a first quarter 2026 earnings conference call and live webcast on May 7, 2026 at 8:30 a.m. ET, with an earnings press release issued earlier that morning.
The live webcast, presentation materials, and a replay will be available in the Investors section of Enovis' website at www.enovis.com.
Enovis (NYSE: ENOV) reported fourth-quarter net sales of $576 million (Q4 growth 3% reported, 2% organic) and full-year 2025 net sales of $2.2 billion (+7% reported, +6% organic). Recon sales grew 10% for the year; P&R grew 4%.
The company recorded a full-year net loss from continuing operations of $1,182 million including a $1,050 million non-cash goodwill impairment; adjusted EBITDA was $403 million. 2026 guidance: revenue $2.31–2.37 billion, adjusted EBITDA $425–435 million, adjusted EPS $3.52–3.73.
Enovis (NYSE: ENOV) reported fourth-quarter and full-year 2025 results on Feb 26, 2026. Full-year net sales were $2.2 billion, up 7% reported and 6% organic; fourth-quarter sales were $576 million, up 3% reported and 2% organic.
The company recorded a full-year goodwill impairment of $1.05 billion (Q4 impairment of $501 million), resulting in net losses of $1,182 million for the year and $519 million in Q4. 2026 guidance: revenue ~$2.31-2.37 billion, adjusted EBITDA $425-435 million, and adjusted EPS $3.52-3.73.
Enovis (NYSE: ENOV) announced management will participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Wednesday, February 11, 2026 in Snowbird, UT. The notice confirms a company presentation but contains no financial data or guidance.
Enovis (NYSE: ENOV) will host a conference call and live webcast to discuss fourth quarter and full year 2025 results on Thursday, February 26, 2026 at 8:30 a.m. ET. An earnings press release will be issued earlier that morning. The live webcast and presentation will be available from the Investors section of Enovis' website at www.enovis.com. U.S. dial-in is (833) 685-0901 and international dial-in is (412) 317-5715. A replay and presentation materials will be posted on the Enovis website later the same day.
Enovis (NYSE: ENOV) said its management team will participate in the 44th Annual J.P. Morgan Healthcare Conference, with a presentation on Monday, January 12, 2026 at 4:30 p.m. PST (7:30 p.m. EST).
A live audio webcast, accompanying presentation slides, and a replay will be available on the company website under Events and Presentations.
Enovis (NYSE: ENOV) appointed Oliver Engert as Chief Administrative Officer, effective January 5, 2026.
In this newly created role, Engert will lead strategy development, drive organizational efficiency, and enhance operational excellence to support the company’s next phase of profitable, capital-efficient growth. Engert joins from McKinsey & Company after 30 years there, most recently as Senior Partner Emeritus, Special Advisor, and will be primarily based in Lewisville, Texas.
Enovis (NYSE: ENOV) reported third-quarter 2025 results for the period ended October 3, 2025, with net sales of $549 million, up 9% reported and 7% organic year‑over‑year. Recon sales rose 12% reported (9% organic); P&R sales grew 6% reported (4% organic). The company reported a GAAP net loss of $571 million driven by a $548 million non‑cash goodwill impairment, and adjusted EBITDA was $95 million (17.3% margin) with adjusted EPS of $0.75. Enovis completed the October divestiture of its Diabetic Footcare business for up to $60 million and raised full‑year 2025 adjusted EBITDA and adjusted EPS guidance, with revenue guidance narrowed to $2.24–2.27 billion.